Lymphoma: Pathology, Diagnosis, and Treatment
Robert Marcus, John W. Sweetenham, Michael E. Williams
Cambridge University Press, Dec 5, 2013 - Medical - 319 pages
Major advances have occurred in the diagnosis and treatment of lymphoma in recent years. Our understanding of the molecular biology and genetics of the disease has increased exponentially, and significant imaging developments have resulted in earlier and more accurate diagnosis. The new edition of this landmark text places these advances in the context of daily clinical practice. Each chapter has been updated to reflect recent developments, including new treatment agents such as immunomodulatory drugs and the next generation of antibodies, and the increasing prognostic role of PET scanning. Results from recent large-scale clinical trials are presented, and pathology and cytogenetics are integrated into discussion of each disease entity, enabling the reader to review all the key diagnostic information in one place. Featuring many color illustrations, and written and edited by leading authorities in the field, Lymphoma provides all the information you need to diagnose and manage these complex disorders.
What people are saying - Write a review
We haven't found any reviews in the usual places.
ABVD aggressive ALCL alemtuzumab allogeneic analysis antibody ASCT associated bendamustine biopsy Blood bone marrow bortezomib Cancer chemotherapy chlorambucil CHOP chromosomal chronic lymphocytic leukemia Clin Oncol clinical trials combination compared cycles cyclophosphamide cytarabine diagnosis diffuse large B-cell disease DLBCL dose doxorubicin etoposide evaluated expression extranodal fludarabine follicular lymphoma gene GHSG high-dose Hodgkin lymphoma IF-RT Immunophenotypically improved infection infiltrate inhibitor involvement large B-cell lymphoma lenalidomide lesions leukemia lymph node lymphocytic lymphoid macroglobulinemia MALT lymphoma mantle cell lymphoma median methotrexate molecular monoclonal months nodal non-Hodgkin’s lymphoma outcome overall patients with relapsed PCNSL peripheral phase II trials phoma prednisone Primary cutaneous prognostic factors protein R-CHOP radiotherapy regimen relapsed or refractory remission reported response rate retrospective risk rituximab stage stem cell transplantation subtypes survival T-cell lymphoma therapeutic therapy tion toxicity translocation treatment tumor versus vincristine